ANTEOTECH LTD — Board/Management Information 2016

Jul 26, 2016

==> picture [276 x 85] intentionally omitted <==

APPOINTMENT OF COO – Australian Operations

For Immediate Release:

27 July, 2016

• Ms Tamara Mills, MBA BSc appointed Chief Operating Officer of Anteo’s Australian Operations

• Strong experience in Pharmaceutical and Medical Device commercialisation

Anteo Diagnostics announces the appointment of Ms Tamara Mills as COO of Australian operations.

Ms Mills has over 10 years’ experience in the successful development and commercialisation of innovative medical technologies from research and development through to manufacturing, sales and marketing. Tamara holds degrees in both science and business, and has an extensive background in the pharmaceutical and medical device sectors, having held both technical and commercial executive level positions within Australia and Internationally.

Tamara’s last position was Director of the Cardiology Business Division for Jubilant DraxImage, a Global pharmaceutical and medical device company based in North America, leading product development and commercialisation, and reporting directly to the CEO and board of Directors within Jubilant Life Sciences.

Dr Jef Vangenechten said: “We are fortunate to have an experienced operational executive like Tamara join us at Anteo. Tamara’s skills in developing and commercialising new products will contribute significantly as we position and commercialize Anteo’s unique nanocoating technology platform. Her valuable experience in linking R&D developments to market and customer needs will give direction to the future developments of our technology, and her commercial experience will add great value to the development of new business opportunities.”

Tamara Mills said: “I left Australia in 2010 to enhance my experience in commercialisation of innovative products. After six years of doing business in the US, Europe, Asia and South America, I am looking forward to an executive position in Australia where I can make a substantial impact and contribution to Australian medical technology innovation and commercialization. Anteo’s nano-coating technology, with its breadth of applications is an exciting opportunity and I am looking forward to being part of the team in Australia and Belgium to further the development and commercialisation activities in the newly expanded Anteo Group”.

As part of Ms Mills package, the Board has agreed to issue her 2,000,000 options to acquire Fully Paid Ordinary Shares. These options will have an exercise period of 4 years, with an exercise price based on 150% of the 10 day VWAP on the issue date and will vest 1 year from the date of issue.

Ms Mills will take up her position in Brisbane on 15 August 2016.

==> picture [108 x 89] intentionally omitted <==

==> picture [268 x 55] intentionally omitted <==

==> picture [276 x 85] intentionally omitted <==

About Anteo Diagnostics Limited

Anteo Diagnostics Limited (ASX: ADO) is a global nanochemistry technology company, developing and commercializing products for the life sciences and clinical diagnostics, medical devices, and energy, and bioseparations markets. The Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent bindings with the gentleness of passive bindings through multi-point chelation. Used as a binder, coating or primer, Anteo’s reagents target high-value commercial applications in protein binding and anti-body coupling (e.g point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings in batteries, and this across a broad range of industry sectors.

For more information, please visit www.anteodx.com

==> picture [588 x 139] intentionally omitted <==